$0.43
−1.07%Price chart
Sep 17Sep 22Sep 25Sep 30Oct 5Oct 8Oct 13Oct 16
Key dataOct 16, 2026
Open$0.45
From 52W high−75.98%
Volume4.17M
Market cap$120.79M
P/E (TTM)—
P/S (TTM)56.9x
Div yield—
Key dataOct 16, 2026
Open
$0.45
From 52W high
−75.98%
Volume
4.17M
Market cap
$120.79M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.4x
P/E (TTM)
—
RSI (14)
40.6
MomentumView details →
1D Return
−1.07%
YTD Return
−53.92%
SummaryUpdated Jun 1, 2026
Humacyte, Inc. (NASDAQ:HUMA) is a clinical-stage biotechnology company founded in 2004 and headquartered in Durham, North Carolina. The company went public in December 2020 and specializes in developing bioengineered human tissues for vascular repair and replacement applications. Humacyte has achieved its first commercial milestone with the FDA approval of its flagship product Symvess in 2024 for treating extremity vascular trauma, marking the transition from a pure research and development company to one generating initial commercial revenues.
Similar companies
Latest newsMore news →
Humacyte, Inc. reported that the number of hospitals ordering Symvess increased 44% in the third quarter, from 34 at the end of the second quarter to 49 as of September 30, 2026.1d agoHumacyte, Inc. shares fell 7.88% to $0.36 from the prior session's close.3d agoHumacyte shares closed at $0.48, down 4.26% from the prior session.10d ago